Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Why Biotech Stocks Rallied on Biogen's Alzheimer's Test
by Ryan McQueeney
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
Biogen's Alzheimer Disease Candidate Succeeds in Phase II
by Zacks Equity Research
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise
Top Analyst Reports for Johnson & Johnson, Biogen & General Motors
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Biogen (BIIB) and General Motors (GM).
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
PTC Therapeutics' Spinal Muscular Atrophy Study Successful
by Zacks Equity Research
PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.
Roche Announces Positive Data on Gazyva and MS Drug Ocrevus
by Zacks Equity Research
Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus.
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
by Zacks Equity Research
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
Drug Stocks: The Next Hot Industry or Value Traps?
by Tracey Ryniec
These 5 stocks look dirt cheap but is it too good to be true?
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
by Zacks Equity Research
Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.
Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset
by Zacks Equity Research
Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.
Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for the label expansion of Rituxan for the treatment of adults with pemphigus vulgaris.
Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus
by Zacks Equity Research
Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.
Why is Biogen (BIIB) Up 6.7% Since Its Last Earnings Report?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents
by Zacks Equity Research
The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
by Zacks Equity Research
The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down
by Zacks Equity Research
Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.
Biogen (BIIB) Q1 Earnings Beat, Sales Miss
by Zacks Equity Research
Biogen (BIIB) beat estimates for earnings but marginally misses the same for sales in Q1. The company's oral MS drug Tecfidera sales increased year over year.
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
by Zacks Equity Research
Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.
Novartis (NVS) Reports Encouraging Data on MS Candidate
by Zacks Equity Research
Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.
What's in Store for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
On the Q1 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar
by Zacks Equity Research
Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).